###begin article-title 0
Dysfunctional KEAP1-NRF2 Interaction in Non-Small-Cell Lung Cancer
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Nuclear factor erythroid-2 related factor 2 (NRF2) is a redox-sensitive transcription factor that positively regulates the expression of genes encoding antioxidants, xenobiotic detoxification enzymes, and drug efflux pumps, and confers cytoprotection against oxidative stress and xenobiotics in normal cells. Kelch-like ECH-associated protein 1 (KEAP1) negatively regulates NRF2 activity by targeting it to proteasomal degradation. Increased expression of cellular antioxidants and xenobiotic detoxification enzymes has been implicated in resistance of tumor cells against chemotherapeutic drugs.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 468 473 468 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Here we report a systematic analysis of the KEAP1 genomic locus in lung cancer patients and cell lines that revealed deletion, insertion, and missense mutations in functionally important domains of KEAP1 and a very high percentage of loss of heterozygosity at 19p13.2, suggesting that biallelic inactivation of KEAP1 in lung cancer is a common event. Sequencing of KEAP1 in 12 cell lines and 54 non-small-cell lung cancer (NSCLC) samples revealed somatic mutations in KEAP1 in a total of six cell lines and ten tumors at a frequency of 50% and 19%, respectively. All the mutations were within highly conserved amino acid residues located in the Kelch or intervening region domain of the KEAP1 protein, suggesting that these mutations would likely abolish KEAP1 repressor activity. Evaluation of loss of heterozygosity at 19p13.2 revealed allelic losses in 61% of the NSCLC cell lines and 41% of the tumor samples. Decreased KEAP1 activity in cancer cells induced greater nuclear accumulation of NRF2, causing enhanced transcriptional induction of antioxidants, xenobiotic metabolism enzymes, and drug efflux pumps.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
This is the first study to our knowledge to demonstrate that biallelic inactivation of KEAP1 is a frequent genetic alteration in NSCLC. Loss of KEAP1 function leading to constitutive activation of NRF2-mediated gene expression in cancer suggests that tumor cells manipulate the NRF2 pathway for their survival against chemotherapeutic agents.
###end p 6
###begin p 7
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Biallelic inactivation ofKEAP1, a frequent genetic alteration in NSCLC, is associated with activation of the NRF2 pathway which leads to expression of genes that contribute to resistance against chemotherapeutic drugs.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 90 96 <span type="species:ncbi:9606">people</span>
###xml 549 555 <span type="species:ncbi:9606">people</span>
###xml 829 835 <span type="species:ncbi:9606">people</span>
Lung cancer is the most common cause of cancer-related death worldwide. More than 150,000 people in the US alone die every year from this disease, which can be split into two basic types-small cell lung cancer and non-small-cell lung cancer (NSCLC). Four out of five lung cancers are NSCLCs, but both types are mainly caused by smoking. Exposure to chemicals in smoke produces changes (or mutations) in the genetic material of the cells lining the lungs that cause the cells to grow uncontrollably and to move around the body. In more than half the people who develop NSCLC, the cancer has spread out of the lungs before it is diagnosed, and therefore can't be removed surgically. Stage IV NSCLC, as this is known, is usually treated with chemotherapy-toxic chemicals that kill the fast-growing cancer cells. However, only 2% of people with stage IV NSCLC are still alive two years after their diagnosis, mainly because their cancer cells become resistant to chemotherapy. They do this by making proteins that destroy cancer drugs (detoxification enzymes) or that pump them out of cells (efflux pumps) and by making antioxidants, chemicals that protect cells against the oxidative damage caused by many chemotherapy agents.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 27 35 <span type="species:ncbi:9606">patients</span>
To improve the outlook for patients with lung cancer, researchers need to discover exactly how cancer cells become resistant to chemotherapy drugs. Detoxification enzymes, efflux pumps, and antioxidants normally protect cells from environmental toxins and from oxidants produced by the chemical processes of life. Their production is regulated by nuclear factor erythroid-2 related factor 2 (NRF2). The activity of this transcription factor (a protein that controls the expression of other proteins) is controlled by the protein Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 holds NRF2 in the cytoplasm of the cell (the cytoplasm surrounds the cell's nucleus, where the genetic material is stored) when no oxidants are present and targets it for destruction. When oxidants are present, KEAP1 no longer interacts with NRF2, which moves into the nucleus and induces the expression of the proteins that protect the cell against oxidants and toxins. In this study, the researchers investigated whether changes in KEAP1 might underlie the drug resistance seen in lung cancer.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 982 987 982 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
The researchers looked carefully at the gene encoding KEAP1 in tissue taken from lung tumors and in several lung cancer cell lines-tumor cells that have been grown in a laboratory. They found mutations in parts of KEAP1 known to be important for its function in half the cell lines and a fifth of the tumor samples. They also found that about half of the samples had lost part of one copy of the KEAP1 gene-cells usually have two copies of each gene. Five of the six tumors with KEAP1 mutations had also lost one copy of KEAP1-geneticists call this biallelic inactivation. This means that these tumors should have no functional KEAP1. When the researchers checked this by staining the tumors for NRF2, they found that the tumor cells had more NRF2 than normal cells and that it accumulated in the nucleus. In addition, the tumor cells made more detoxification enzymes, efflux proteins, and antioxidants than normal cells. Finally, the researchers showed that lung cancer cells with KEAP1 mutations were more resistant to chemotherapy drugs than normal lung cells were.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
These results indicate that biallelic inactivation of KEAP1 is a frequent genetic alteration in NSCLC and suggest that the loss of KEAP1 activity is one way that lung tumors can increase their NRF2 activity and develop resistance to chemotherapeutic drugs. More lung cancer samples need to be examined to confirm this result, and similar studies need to be done in other cancers to see whether loss of KEAP1 activity is a common mechanism by which tumors become resistant to chemotherapy. If such studies confirm that high NRF2 activity (either through mutation or by some other route) is often associated with a poor tumor response to chemotherapy, then the development of NRF2 inhibitors might help to improve treatment outcomes in patients with chemotherapy-resistant tumors.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
US National Cancer Institute information on and on 
###end p 19
###begin p 20
MedlinePlus entries on  and  UK information on lung cancer
###end p 20
###begin p 21
Wikipedia entries on and  (note that Wikipedia is a free online encyclopedia that anyone can edit)
###end p 21
###begin title 22
Introduction
###end title 22
###begin p 23
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b001">1</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b002">2</xref>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b003">3</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b006">6</xref>
###xml 98 101 <span type="species:ncbi:9606">men</span>
###xml 106 111 <span type="species:ncbi:9606">women</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
Lung carcinomas are the leading cause of cancer deaths in the United States and worldwide in both men and women. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with 65% of these patients presenting with unresectable stage III and IV disease [1]. Chemotherapy for advanced, inoperable NSCLC is generally palliative. The major factor contributing to the failure of chemotherapy in lung cancer is the development of drug resistance [2]. Several studies have shown that the expression of xenobiotic metabolism genes (glutathione-S-transferases [GSTs]), antioxidants (glutathione [GSH]), and drug efflux proteins (multidrug resistance protein [MRP] family) is increased in NSCLC [3-6]. Xenobiotic metabolism enzymes in conjunction with drug efflux proteins act to detoxify cancer drugs, whereas antioxidants confer cytoprotection by attenuating drug-induced oxidative stress and apoptosis.
###end p 23
###begin p 24
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b009">9</xref>
###xml 871 872 863 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 873 874 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b008">8</xref>
###xml 995 996 987 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 997 998 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b008">8</xref>
###xml 1068 1070 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b010">10</xref>
###xml 1071 1073 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b012">12</xref>
Nuclear factor erythroid-2 related factor 2 (NRF2), a cap 'n' collar basic leucine zipper transcription factor, regulates a transcriptional program that maintains cellular redox homeostasis and protects cells from oxidative insult, including from chemotherapeutic agents [7-9]. NRF2 activates transcription of its target genes through binding specifically to the antioxidant response element (ARE) found in those gene promoters. The NRF2-regulated transcriptional program includes a broad spectrum of genes, including ones encoding antioxidants (e.g., gamma-glutamyl cysteine synthetase modifier subunit [GCLm], gamma-glutamyl cysteine synthetase catalytic subunit [GCLc], heme oxygenase-1, superoxide dismutase, glutathione reductase [GSR], glutathione peroxidase, thioredoxin, thioredoxin reductase, peroxiredoxins[PRDX], and cysteine/glutamate transporter [SLC7A11]) [7,8], xenobiotic metabolism enzymes (e.g., NADP[H] quinone oxidoreductase 1 [NQO1], GSTs, and UDP-glucuronosyltransferase) [7,8], and several ATP-dependent drug efflux pumps (e.g., MRP1 and MRP2) [10-12].
###end p 24
###begin p 25
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b013">13</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b014">14</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b015">15</xref>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nrf2</italic>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b016">16</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b017">17</xref>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b018">18</xref>
###xml 922 924 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b011">11</xref>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
Disruption of NRF2 in mice enhances oxidative damage and inflammation in lungs on exposure to cigarette smoke [7], diesel exhaust [13], lipopolysaccharide [14], and allergen [15]. Nrf2-deficient mice have lesser expression of xenobiotic enzymes and are greatly predisposed to tumors induced by carcinogens such as benzo(a)pyrene and aflatoxin [16]. By virtue of its central role in the transactivation of detoxification genes involved in the cellular responses to oxidative or electrophilic stresses, NRF2 activation is being targeted for cancer chemoprevention [17]. Recent studies have also demonstrated that NRF2 protects against apoptosis induced by oxidants and also by FAS ligand [7,18]. Phosphorylation of NRF2 by protein kinase(s) associated with the MAPK/ERK signaling cascade increases stabilization of NRF2 and has been proposed as an important mechanism leading to increased expression of ARE-dependent genes [11].
###end p 25
###begin p 26
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b019">19</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b020">20</xref>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b021">21</xref>
###xml 473 481 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g001">Figure 1</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b022">22</xref>
###xml 1022 1023 1022 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b023">23</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b024">24</xref>
###xml 1114 1119 1114 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Kelch-like ECH-associated protein 1 (KEAP1) is a cytoplasmic anchor of NRF2 that also functions as a substrate adaptor protein for a Cul3-dependent E3 ubiquitin ligase complex to maintain steady-state levels of NRF2- and NRF2-dependent transcription [19,20]. KEAP1 is located at 19p13.2 and has three major domains: an N-terminal broad complex, tramtrack, and bric-a-brac (BTB) domain; a central intervening region (IVR); and a series of six C-terminal Kelch repeats [21] (Figure 1). The Kelch repeats of KEAP1 bind the Neh2 domain of NRF2, whereas the IVR and BTB domains are required for the redox-sensitive regulation of NRF2 through a series of reactive cysteines present throughout this region [22]. KEAP1 constitutively suppresses NRF2 activity in the absence of stress; however, oxidants, xenobiotics, and electrophiles hamper the KEAP1-mediated proteasomal degradation of NRF2, which results in increased nuclear accumulation and, in turn, the transcriptional induction of target genes that ensure cell survival. [7,23] Recently, Padmanabhan et al. [24] reported a heterozygous somatic mutation (G430C) in KEAP1 in one lung cancer tumor and a G364C mutation in an adenocarcinoma and a small cell lung cancer cell line.
###end p 26
###begin p 27
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
To investigate the NRF2-KEAP1 pathway in lung cancer we first examined the status of the KEAP1 locus at 19p13.2. We also sequenced KEAP1 in 12 cell lines and 56 tumor samples obtained from lung cancer patients. Since KEAP1 is an inhibitor of NRF2-mediated gene expression, we monitored the expression of NRF2 and its downstream target genes in lung cancer samples.
###end p 27
###begin title 28
Methods
###end title 28
###begin title 29
Tumor Samples
###end title 29
###begin p 30
###xml 701 709 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st001">Table S1</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Tumors for this study were randomly selected from 700 freshly frozen lung cancer tissues from patients who had undergone complete, curative resection of their disease from 1993 to 2001 at Johns Hopkins Hospital, Baltimore, Maryland, United States. Tumors were macrodissected and only those specimens with greater than 50% neoplastic cells were used. A total of 56 cases of lung tumor, including 40 paired lung tumors and adjacent normal tissues (frozen tissue) and 16 pleural fluid (PF) samples, were chosen in accordance with the Institutional Review Board protocol, and DNA was isolated using DNeasy Kit (Qiagen, Valencia, California, United States). Details of the lung tumor samples are listed in Table S1.
###end p 30
###begin title 31
PCR and Sequence Analysis
###end title 31
###begin p 32
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1396 1404 1396 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st002">Table S2</xref>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
The genomic sequence of human KEAP1 was downloaded from the NCBI human genome database. Primers for PCR amplification and sequencing of KEAP1 were designed using Primer3 software () and synthesized by Integrated DNA Technologies (Coralville, Iowa, United States). PCR amplification of DNA from early passage cell lines or primary tumors (PTs) was carried out using ExTaq Premix from Takara Mirus Biosciences (Madison, Wisconsin, United States) and 10 pmol of each primer. PCR products were directly sequenced after purification (QIAquick PCR purification kit, Qiagen). Sequencing was carried out at the DNA sequencing core facility located at Johns Hopkins University. The sequence data were downloaded, assembled, and analyzed to identify potential genetic alterations. All mutations were confirmed by sequencing in both directions. PCR products from samples showing deletion mutation were reamplified using high-fidelity Taq polymerase (Applied Biosystems, Foster City, California, United States) and cloned into TOPO TA cloning vector (Invitrogen, Carlsbad, California, United States), and five clones from each sample were sequenced. All deletions were present in at least two of the five clones sequenced. Exons harboring mutations were reamplified from the original DNA and sequenced. Chromatograms were analyzed by manual review. Sequences of all the primers used for amplification are in Table S2. The PCR cycling conditions were 94 degreesC (3 min) for one cycle, 94 degreesC (30 s), 65 degreesC (45 s), and 72 degreesC (1 min) for 35 cycles, and a final extension of 72 degreesC (5 min).
###end p 32
###begin title 33
Microsatellite-Based Loss of Heterozygosity Analysis
###end title 33
###begin p 34
###xml 663 668 663 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 801 806 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 808 816 808 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-UM1</italic>
###xml 820 822 820 822 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sub>
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 866 874 866 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-DM1</italic>
###xml 878 880 878 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21</sub>
###xml 909 914 909 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1145 1146 1144 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1581 1589 1549 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st002">Table S2</xref>
###xml 1790 1798 1758 1766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-DM1</italic>
###xml 1803 1811 1771 1779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-UM1</italic>
###xml 184 189 <span type="species:ncbi:9606">human</span>
The Cancer Genome Project at Sanger Institute (Cambridge, United Kingdom) genotyped 829 cell lines with 395 polymorphic CA/GT repeat markers that provide a 10-cM resolution map of the human genome. The markers are sourced from the ABI Prism LD20 set (data available at ). Of the 829 cell lines genotyped, 191 were lung cancer cell lines. We obtained the raw data from Sanger Institute and analyzed it, and the results are presented in the form of a heat map. Fluorescent loss of heterozygosity (LOH) analysis using genomic DNA from matched normal and lung tumor tissues was performed using two novel microsatellite markers. Contig AC011461.5.1.100680, containing KEAP1 flanking sequences, was downloaded from the Ensembl database (). Two pairs of fluorescently labeled microsatellite primers flanking KEAP1 (KEAP-UM1 [CA17], present upstream of the KEAP1 locus, and KEAP-DM1 [CA21], present downstream of the KEAP1 locus) were designed using Primer3 software and synthesized by Integrated DNA Technologies. Briefly, each PCR reaction was performed in a total volume of 10 mul containing 50 ng DNA, 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 200 muM dNTPs, 10 pmol of each primer, and 0.1 U Ampli Taq GOLD DNA polymerase (Applied Biosystems). Cycling conditions were 94 degreesC (10 min) for one cycle, 94 degreesC (30 s), 66-67 degreesC (30 s), and 72 degreesC (30 s) for 25 cycles, and a final extension of 72 degreesC (20 min), in a MJ Research tetrad PCR System (Bio-Rad, Hercules, California, United States). Details of the primer sequences are listed in Table S2. The data were analyzed by the ABI Genescan and Genotyper software packages (PerkinElmer, Wellesley, Massachusetts, United States), and allelic loss was scored. The sequence and allele size range for KEAP-DM1 and KEAP-UM1 were determined prior to their use in the analysis of the normal and tumor-matched lung cancer samples. In our system, a relative allele ratio of less than 0.6, which correlates with an allele loss of approximately 40%, was defined as LOH. The LOH was confirmed at least twice for each marker.
###end p 34
###begin title 35
Heat Maps
###end title 35
###begin p 36
Heat maps were constructed using GeneCluster and Treeview software (M. Eisen; ). For displaying gene expression values for the different normal and cancer cell lines, the relative fold changes for individual cell lines were normalized to the maximum fold change value across all cell lines, for a particular gene.
###end p 36
###begin title 37
Western Blot Analysis
###end title 37
###begin p 38
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
To obtain total protein lysates, cancer cells or tissues were lysed in 50 mM Tris (pH 7.2), 1% Triton X-100 containing Halt Protease Inhibitor cocktail (Pierce, Rockford, Illinois, United States) and centrifuged at 12,000g for 15 min at 4 degreesC. To obtain nuclear extracts, NE-PER Nuclear Extraction Reagents (Pierce) were used. Protein concentrations were estimated by the BCA method (Pierce).
###end p 38
###begin p 39
###xml 304 305 302 303 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</bold>
For immunoblot analysis, 30 mug and 100 mug of protein from nuclear extracts and total protein lysates, respectively, were used and resolved on 10% SDS-PAGE gels. Proteins were transferred onto PVDF membranes, and the following antibodies were used for immunoblotting: anti-KEAP1 (gift from M. Velichkova, University of California San Diego, La Jolla, California, United States), anti-NRF2 (H-300; Santa Cruz Biotechnology, Santa Cruz, California, United States), anti-Lamin B1 (Santa Cruz Biotechnology), and anti-GAPDH (Imgenex, Sorrento Valley, California, United States). All primary antibodies were diluted in PBS-T/5% nonfat dry milk and incubated overnight at 4 degreesC.
###end p 39
###begin title 40
Enzyme Assay
###end title 40
###begin p 41
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b008">8</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b025">25</xref>
Enzyme activities of GST, GSR, and NQO1 were determined in the total protein lysates by following methods previously described [8]. Total glutathione (oxidized and reduced) was determined using a modified Tietze method [25] by measuring reduction of 5,5'-dithiobis-2-nitrobenzoic acid in a GSR-coupled assay.
###end p 41
###begin title 42
In Vitro Transcription/Translation
###end title 42
###begin p 43
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human KEAP1 and NRF2 cDNA was in vitro transcribed and translated using in vitro transcription/translation reactions. These were performed in T7 TNT reticulocyte lysate (Promega, Madison, Wisconsin, United States) following the supplier's instructions.
###end p 43
###begin title 44
Immunohistochemistry
###end title 44
###begin p 45
###xml 145 156 <span type="species:ncbi:3704">horseradish</span>
###xml 206 212 <span type="species:ncbi:9986">rabbit</span>
Formalin-fixed tissues were treated with anti-NRF2 antibody (H-300, Santa Cruz Biotechnology) at a dilution of 1:250 for 1 h and developed using horseradish peroxidase (Dako, Glostrup, Denmark). Non-immune rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, United States) was used as a negative control. To demonstrate the specificity of antibody staining, we preincubated the anti-NRF2 antibody with NRF2 and luciferase in vitro transcribed and translated protein, respectively, for 30 min and then carried out immunohistochemical staining.
###end p 45
###begin title 46
Real-Time RT-PCR
###end title 46
###begin p 47
###xml 363 364 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 510 572 508 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1, NRF2, GCLc, GCLm, GSR, PRDX1, GSTA3, GSTA2, NQO1, MRP1,</italic>
###xml 577 581 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP2</italic>
###xml 504 509 <span type="species:ncbi:9606">human</span>
Total RNA was extracted from cells using RNeasy kit (Qiagen) and was quantified by UV absorbance spectrophotometry. The reverse transcription reaction was performed by using the Superscript First-Strand Synthesis System (Invitrogen) in a final volume of 20 mul containing 2 mug of total RNA, 100 ng of random hexamers, 1x reverse transcription buffer, 2.5 mM MgCl2, 1 mM dNTP, 10 U of RNaseOUT, 20 U of Superscript reverse transcriptase, and DEPC-treated water. Quantitative real-time RT-PCR analyses of human KEAP1, NRF2, GCLc, GCLm, GSR, PRDX1, GSTA3, GSTA2, NQO1, MRP1, and MRP2 were performed by using Assay-on-Demand primers and probe sets from Applied Biosystems. Assays were performed by using the ABI 7000 Taqman system (Applied Biosystems). beta-actin was used for normalization.
###end p 47
###begin title 48
Plasmid Construction
###end title 48
###begin p 49
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 429 437 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st002">Table S2</xref>
###xml 17 22 <span type="species:ncbi:9606">human</span>
Plasmid encoding human KEAP1 cDNA in pCMV6-XL5 was purchased from Origene Technologies (Rockville, Maryland, United States). Glycine-to-serine mutations, leucine-to-arginine mutations, and a single nucleotide deletion were introduced into the KEAP1 expression vector by using a site-directed mutagenesis kit (Stratagene, La Jolla, United States). Details of the site-directed mutagenesis primers used in this study are listed in Table S2.
###end p 49
###begin title 50
Cell Culture and Reagents
###end title 50
###begin p 51
HBE4, NL20, A549, H460, H1435, H292, H23, H358, H1299, H1993, H1395, and H838 cells were purchased from American Type Culture Collection (Manassas, Virginia, United States) and cultured under recommended conditions. BEAS2B cells were provided by S. Reddy (Johns Hopkins University, Baltimore, Maryland, United States). All transfections were carried out using Lipofectamine 2000 (Invitrogen).
###end p 51
###begin title 52
Generation of Stable Transfectants
###end title 52
###begin p 53
###xml 113 121 112 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NQO1-ARE</italic>
H838 cells overexpressing ARE luciferase reporter plasmid were obtained by transfecting H838 cells with 3 mug of NQO1-ARE reporter plasmid and 0.3 mug of pUB6 empty vector (Invitrogen). Stable transfectants were selected using Blasticidin at a concentration of 6 mug/ml. Stable clones were expanded and screened for the expression of ARE luciferase.
###end p 53
###begin title 54
Luciferase Assay
###end title 54
###begin p 55
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-KEAP1</italic>
H838 cells stably expressing NQO1-ARE luciferase were seeded onto a 24-well dish at a density of 0.2 x 106 cells/ml for 12 h before transfection. WT-KEAP1 cDNA constructs along with the mutant cDNA constructs (G333C and L413R) were transfected into the cells along with pRL-TK plasmid expressing Renilla luciferase as a transfection control. Twenty-four hours after transfection, cells were lysed and both firefly and Renilla luciferase activities were measured with a Dual-Luciferase Reporter Assay System (Promega).
###end p 55
###begin title 56
siRNA Duplex Screening and Transfection
###end title 56
###begin p 57
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 399 404 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 959 960 959 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
The siRNA sequence targeting NRF2 corresponds to the coding region nucleotides 1903-1921 (5'-GTAAGAAGCCAGATGTTAA-3') in the NRF2 cDNA. The NRF2 siRNA duplex with the following sense and antisense sequences was used: 5'-GUAAGAAGCCAGAUGUUAAdUdU-3' (sense) and 3'-dUdUCAUUCUUCGGUCUACAATT-5' (antisense). KEAP1 siRNA corresponds to the coding region nucleotides 1545-1563 (5'-GGGCGTGGCTGTCCTCAAT-3') in KEAP1 transcript variant 2. The KEAP1 siRNA duplex with the following sense and antisense sequences was used: 5'-GGGCGUGGCUGUCCUCAAUdUdU-3' (sense) and 3'-dUdUCCCGCACCGACAGGAGUUA-5' (antisense). To confirm the specificity of the inhibition, the siCONTROL non-targeting siRNA 1 (NS siRNA; 5'-UAGCGACUAAACACAUCAAUU-3') with microarray-defined signature was used as a negative control. All of the siRNA duplexes were synthesized by Dharmacon Research (Lafayette, Colorado, United States). Cells in the exponential growth phase were plated at a density of 0.2 x 106 cells/ml, grown for 12 h, and transfected twice at an interval of 48 h with 50 nM siRNA duplexes using Lipofectamine 2000 and OPTI-MEM reduced serum medium (Invitrogen) according to the manufacturer's recommendations. Concentrations of siRNAs were chosen on the basis of dose-response studies (data not shown).
###end p 57
###begin title 58
MTT Cell Viability Assay
###end title 58
###begin p 59
The in vitro drug sensitivity to etoposide and carboplatin was assessed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay. Cells were plated at a density of 10,000 cells for BEAS2B, 5,000 cells for A549, H460, and H838, and 20,000 cells for H1435 in 96-well plates. They were allowed to recover for 12 h and then exposed to various concentrations of etoposide and carboplatin for 72 h. After 72 h, drug cytotoxicity was evaluated by using a MTT reduction conversion assay (Sigma, Saint Louis, Missouri, United States). Forty microliters of MTT at 5 mg/ml concentration was added to each well, and incubation was continued for 4 h. The formazan crystals resulting from mitochondrial enzymatic activity on MTT substrate were solubilized with 200 mul of dimethyl sulfoxide, and absorbance was measured at 570 nm by using a SpectraMAX microplate reader (Molecular Devices, Sunnyvale, California, United States). Each combination of cell line and drug concentration was set up in eight replicate wells, and the experiment was repeated three times. Cell survival was expressed as absorbance relative to that of untreated controls. Results are presented as means +/- standard deviation (SD).
###end p 59
###begin title 60
Results
###end title 60
###begin title 61
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Somatic Alterations in KEAP1 in Lung Cancer Cell Lines
###end title 61
###begin p 62
###xml 364 372 364 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g002">Figure 2</xref>
###xml 410 415 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 749 756 749 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030420-t001">Table 1</xref>
###xml 1029 1038 1029 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g002">Figures 2</xref>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-sg001">S1</xref>
###xml 1258 1263 1258 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1398 1406 1398 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st003">Table S3</xref>
###xml 1295 1300 <span type="species:ncbi:9606">human</span>
Evaluation of LOH at 19p13.2 in 191 lung cancer cell lines from the Cancer Genome Project database at the Sanger Institute revealed allelic loss in 44% (80/181; ten lines were non-informative) of the cell lines. Of the 72 NSCLC cell lines analyzed in this study, 61% (44/72) showed homozygous typing for at least two consecutive microsatellite markers at 19p13.2 (Figure 2A). To determine whether mutations in KEAP1 were present in NSCLC, we first amplified and sequenced all five protein-coding exons and intron-exon boundaries of the KEAP1 gene in a set of 12 lung cancer cell lines. Sequencing of KEAP1 in these cell lines revealed homozygous mutations in A549, H460, H838, and H1435, whereas H1395 and H1993 were heterozygous for mutant allele (Table 1). We identified five different mutations, among which four were non-conservative amino acid substitutions. A nonsense mutation involving G-T transversion in the fourth exon was detected in the H838 cell line. Representative electropherograms of the mutations are shown in Figures 2B and S1. The microsatellite database at the Sanger Institute showed that the H460, A549, and H838 cell lines had allelic loss (LOH) at 19p13.2. H1435 was not included in the Sanger Institute database. We also sequenced KEAP1 in four non-malignant (normal) human lung epithelial cell lines (BEAS2B, NL20, HBE4, and NHBE) and found only the wild-type sequence (Table S3).
###end p 62
###begin title 63
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Somatic Alterations in KEAP1 in Lung Cancer Tumor Tissues
###end title 63
###begin p 64
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 360 368 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st001">Table S1</xref>
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st001">Table S1</xref>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 626 633 626 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030420-t001">Table 1</xref>
###xml 781 789 781 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g002">Figure 2</xref>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
To determine whether mutations in KEAP1 are present in lung cancer tumors, we amplified and sequenced KEAP1 in 40 primary lung tumors (25 of which were paired with normal tissue samples) and 16 PF samples from lung cancer patients at Johns Hopkins Hospital. The PTs included 19 adenocarcinoma, six large cell carcinoma, and 15 squamous cell carcinoma samples (Table S1). The PF samples included 14 non-small-cell adenocarcinoma and two small cell carcinoma samples (Table S1). Out of 40 PTs sequenced, three tumors (PT-23, PT-29, and PT-35) showed non-conservative amino acid substitution in the IVR and BTB domains of KEAP1 (Table 1). PT-23 (an adenocarcinoma) and PT-35 (a large cell carcinoma) had identical mutations resulting in Q-L amino acid substitution in the IVR domain (Figure 2B). In addition to this, three PTs (PT-17, PT-18, and PT-31) showed deletion mutation in the IVR and Kelch domains, resulting in frameshift and premature termination codons. Of the 16 PF samples, two samples (PF-8 and PF-9) showed identical 18-bp deletions leading to loss of six amino acids in the sixth Kelch domain. PF-4 had a G-insertion in the third exon resulting in frameshift mutation and truncated KEAP1 protein. I-V substitution was detected in sample PF-3.
###end p 64
###begin p 65
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 107 115 107 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-UM1</italic>
###xml 120 129 120 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-DM1,</italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 499 507 499 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g002">Figure 2</xref>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 778 783 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 933 943 933 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-sg001">Figures S1</xref>
###xml 948 950 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-sg002">S2</xref>
To ascertain the status of the KEAP1 locus in primary lung tumors, we designed two microsatellite markers, KEAP-UM1 and KEAP-DM1, that closely flank the KEAP1 gene (within ~300 kb on either side). We genotyped the PTs and their corresponding normal DNA samples using these two markers. PF DNA samples were not used for the LOH studies because the corresponding normal DNA was not available. Of the 39 pairs of lung tumors genotyped, 16 tumors (41%) demonstrated LOH for at least one of the markers (Figure 2C). Six tumors showed only microsatellite instability in this region. Five out of six tumors harboring KEAP1 mutation also demonstrated LOH at these loci. In summary, out of 56 samples sequenced, 54 were NSCLC tumor samples and ten (10/54) of these harbored mutations in KEAP1. Interestingly, nine of the ten mutations were identified in adenocarcinomas. Representative electropherograms of the mutations and LOH are shown in Figures S1 and S2.
###end p 65
###begin title 66
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Biological Effect of KEAP1 Mutation in Lung Cancer
###end title 66
###begin p 67
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 343 351 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g003">Figure 3</xref>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 534 542 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g003">Figure 3</xref>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 627 635 627 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g003">Figure 3</xref>
###xml 1063 1072 1063 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-sg003">Figure S3</xref>
To study the localization of NRF2 in primary lung tumors, we performed immunohistochemistry on primary lung tumor tissues using anti-NRF2 antibody. Prominent NRF2 staining was detected in both the nucleus and cytoplasm of tumor tissue. All four PT tissues harboring KEAP1 mutations showed increased NRF2 staining in the nucleus and cytoplasm (Figure 3A, part a). Three tumor tissues (3/5) with wild-type KEAP1 also demonstrated increased NRF2 staining, whereas the normal bronchus from the same individuals showed very weak staining (Figure 3A, parts c and d). Two tumor tissues with wild-type KEAP1 showed very weak staining (Figure 3A, part b). We also did immunohistochemistry on five normal bronchi and did not find any significant staining. To confirm the specificity of anti-NRF2 antibody staining, we used in vitro transcribed/translated NRF2 and luciferase (negative control) protein. Incubation of anti-NRF2 antibody with NRF2 protein dramatically reduced the staining, whereas incubation with luciferase protein had no effect on NRF2 antibody staining (Figure S3).
###end p 67
###begin p 68
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 419 427 419 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g003">Figure 3</xref>
We also studied levels of known NRF2 targets in tumor samples by measuring NQO1 and GST enzyme activities and total GSH levels in 13 pairs of primary NSCLC tumors and adjacent normal tissues. Among these, four pairs (4/13) of samples were from individuals harboring KEAP1 mutation. Both NQO1 and total GST activities and GSH levels were significantly higher in tumor tissues than in their corresponding normal bronchi (Figure 3B).
###end p 68
###begin p 69
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 423 432 423 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g004">Figures 4</xref>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g004">4</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-sg004">S4</xref>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 746 754 746 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g004">Figure 4</xref>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP2,</italic>
###xml 879 883 879 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 947 951 947 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NQO1</italic>
###xml 956 959 956 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSR</italic>
###xml 981 984 981 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSH</italic>
###xml 1035 1043 1035 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g005">Figure 5</xref>
###xml 1086 1091 1086 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1176 1181 1176 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1255 1263 1255 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g004">Figure 4</xref>
###xml 1386 1395 1386 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g004">Figures 4</xref>
###xml 1397 1398 1397 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g004">4</xref>
###xml 1404 1406 1404 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-sg004">S4</xref>
To determine whether KEAP1 mutations correlated with NRF2 activation, we performed immunoblot analysis to examine the nuclear accumulation of NRF2. For this study, we selected four NSCLC cell lines-H460, A549, H1435, and H838-all harboring KEAP1 mutations, and three non-malignant (normal) cell lines-BEAS2B, NL20, and HBE4. Cancer cells demonstrated increased nuclear localization of NRF2 in comparison with normal cells (Figures 4A-4C and S4). Total NRF2 level was also higher in cancer cells, suggesting that there was increased stabilization of NRF2 in the absence of functional KEAP1. Real-time RT-PCR analysis of NRF2 and NRF2-dependent target genes revealed that the majority of the NRF2 target genes were upregulated in the cancer cells (Figure 4D). Expression of MRP2, known to confer drug resistance, was 100- to 1,000-fold higher in cancer cells. Transcript levels of NRF2 did not vary considerably between the two groups. As expected, NQO1 and GSR activities and total GSH levels were significantly higher in cancer cells (Figure 5). We also analyzed the relative levels of KEAP1 transcript and protein in cancer cells and normal cells. Importantly, expression of KEAP1 mRNA was downregulated in three cancer cell lines-A549, H1435, and H838 (Figure 4D)-and KEAP1 protein was downregulated in all four cancer cell lines in comparison with expression in non-malignant cells (Figures 4A-4C and S4).
###end p 69
###begin title 70
Somatic Mutations Reduce KEAP1-Mediated Repression of NRF2
###end title 70
###begin p 71
###xml 261 266 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 625 633 625 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g006">Figure 6</xref>
###xml 854 859 854 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2,</italic>
###xml 882 887 882 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 932 966 932 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2, NQO1, GSR, GCLc, GCLm, MRP1,</italic>
###xml 971 975 971 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP2</italic>
###xml 1101 1105 1101 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 1142 1146 1142 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 1232 1240 1232 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g006">Figure 6</xref>
###xml 1270 1275 1270 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1357 1365 1357 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g006">Figure 6</xref>
To determine the functional consequences of tumor-derived mutations on KEAP1 activity and resultant increases in NRF2 activity, we generated cDNAs harboring the same mutations seen in tumor cell lines, A549 (G333C) and H1435 (L413R). We also generated a mutant KEAP1 construct harboring a single base pair deletion seen in PT-18. We transfected the wild-type and mutant constructs of KEAP1 into H838 cells stably expressing an ARE reporter. Importantly, all of the three mutants of KEAP1 could not repress the activity of NRF2, whereas overexpression of WT-KEAP1 completely abolished the NRF2-mediated ARE reporter activity (Figure 6A). To further demonstrate that NRF2 activation contributes to the increased expression of antioxidants, xenobiotic metabolism enzymes, and drug efflux pumps in cancer cells, we challenged A549 cells with siRNA targeting NRF2, and BEAS2B cells with KEAP1 siRNA. We measured the transcript levels of NRF2, NQO1, GSR, GCLc, GCLm, MRP1, and MRP2 by real-time RT-PCR. A non-targeting siRNA (NS siRNA) with microarray-defined signature was used as control. Transfection of NRF2 siRNA in cancer cells decreased the NRF2 message by 80% and simultaneously downregulated the expression of NRF2 target genes (Figure 6B). Conversely, inhibition of KEAP1 expression by siRNA induced the expression of NRF2-driven genes in BEAS2B cells (Figure 6C).
###end p 71
###begin title 72
Constitutive Activation of NRF2 Confers Chemoresistance
###end title 72
###begin p 73
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 315 323 315 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030420-g007">Figure 7</xref>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
To elucidate a possible role for NRF2 in conferring chemoresistance, we analyzed the drug resistance profile of normal lung epithelial cells and cancer cells harboring KEAP1 mutation. Cells were exposed to various concentrations of etoposide and carboplatin, and cell viability was measured after 72 h. As shown in Figure 7, BEAS2B cells with wild-type KEAP1 demonstrated enhanced sensitivity to both the drugs when compared with that of cancer cells. Reduced chemosensitivity of cancer cells with high NRF2 activity suggests that NRF2 contributes to drug resistance by regulating the expression of several plasma membrane efflux pumps, such as MRP1 and MRP2, and phase II detoxification enzymes.
###end p 73
###begin title 74
Discussion
###end title 74
###begin p 75
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b008">8</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b015">15</xref>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b026">26</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b027">27</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b028">28</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b029">29</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b030">30</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b026">26</xref>
###xml 1145 1152 1145 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030420-t001">Table 1</xref>
###xml 1555 1557 1555 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b031">31</xref>
###xml 1972 1977 1972 1977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1540 1547 <span type="species:ncbi:4097">tobacco</span>
NRF2, a bZIP transcription factor, activates cellular rescue pathways against oxidative injury, inflammation, apoptosis, and carcinogenesis through transcriptional induction of a broad spectrum of genes involved in xenobiotic detoxification and antioxidant protection [7,8,15]. KEAP1 anchors the NRF2 transcription factor within the cytoplasm, targeting it for ubiquitination and proteasomal degradation, thus repressing its ability to induce cytoprotective genes. LOH at the short arm of Chromosome 19 (19p13.2), where KEAP1 is located, has been reported in lung cancer [26,27], breast carcinoma [28], prostate cancer [29], oral cancer [30], and gall bladder carcinoma. A genome-wide search for LOH in lung cancer cell lines identified Chromosome 19p as a candidate tumor suppressor region showing more than 60% LOH [26]. Evaluation of LOH at 19p13.2 in lung cancer cell lines from the Cancer Genome Project database at the Sanger Institute revealed allelic losses in 61% of the NSCLC cell lines. We detected point mutations leading to non-conservative amino acid substitutions and nonsense mutations in 50% (6/12) of the cell lines sequenced (Table 1), and all the mutations altered highly conserved amino acid residues located in the Kelch or IVR domain of the KEAP1 protein, suggesting that these mutations would likely abolish KEAP1 repressor activity. Three cell lines-A549, H838, and H1435-displayed G-T transversions, the type of DNA damage expected from bulky DNA adducts caused by the polycyclic hydrocarbons and nitrosoamines in tobacco smoke [31]. Only the mutant allele, and not the wild-type, was detected in the H460, A549, H1435, and H838 cell lines, which suggests that the mutations were either homozygous (which is unlikely) or hemizygous (with corresponding LOH affecting the other allele). The microsatellite database at the Sanger Institute revealed that H460, A549, and H838 cell lines had allelic loss at 19p13.2, which confirms that the wild-type KEAP1 allele was lost by LOH and that the retained allele was inactivated by somatic mutations. H1435 was not included in the Sanger Institute database.
###end p 75
###begin p 76
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 972 977 972 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1014 1019 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1255 1260 1255 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1285 1291 1285 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1;</italic>
###xml 1375 1380 1375 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1398 1400 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b032">32</xref>
###xml 1683 1691 1683 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st001">Table S1</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Sequencing of KEAP1 in 40 primary lung tumors and 16 PF samples from lung cancer patients revealed deletion, insertion, missense, and frameshift mutations in KEAP1 in a total of ten tumors, and the frequency of mutations in PTs and PF was 15% (6/40) and 25% (4/16), respectively. Most of the mutations affected highly conserved amino acids located in functionally important domains of KEAP1. We found four different deletions and one single base pair insertion, and all of these alterations (except the 18-bp deletion) introduced a premature stop codon that resulted in a truncated KEAP1 protein. All sequence alterations in this group were heterozygous in tumor DNA and found only in the smokers. Interestingly, the majority (9/10) of these mutations were detected only in adenocarcinomas. No mutations were detected in the paired normal tissue, which confirms that the tumor-derived mutations were somatic in origin. An overall mutation frequency of 19% (10/54) for the KEAP1 gene in NSCLC tissues suggests that KEAP1 mutation is a frequent genetic alteration in NSCLC. Microsatellite-based genotyping of PT and paired normal tissues (39 pairs) demonstrated LOH for at least one of the markers in 41.0% (16/39) of the PTs. Five of the six PTs harboring KEAP1 mutations showed LOH of KEAP1; thus, as defined by the Knudson two-hit model, there was biallelic inactivation of KEAP1 in these tumors [32]. In addition, given the intrinsic difficulties of genetic analysis in PTs, which are invariably contaminated with normal cells, we expect this frequency of mutation and LOH to be an underestimate. Detection of KEAP1 alterations in early stages of lung tumor development (stage IB, Table S1) further suggests that loss of KEAP1 function may be an early event in lung cancer pathogenesis. Future studies aimed at systematic evaluation of KEAP1 status in preinvasive preneoplastic lesions such as hyperplasia, dysplasia, and carcinoma in situ, as well as in late-stage invasive carcinoma, will provide insights regarding the role of the KEAP1-NRF2 pathway in tumor progression.
###end p 76
###begin p 77
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Keap1</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Keap1</italic>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b023">23</xref>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 349 355 349 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1,</italic>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b024">24</xref>
###xml 601 602 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
Keap1-null mutation in mice results in postnatal lethality because of constitutive Nrf2 activation, whereas heterozygous mutation of Keap1 has no effect on Nrf2 activity [23]. This finding suggests that loss of both functional KEAP1 alleles is essential for constitutive activation of NRF2-mediated gene expression. Thus, a heterozygous mutation in KEAP1, as reported recently [24], may not effect NRF2-mediated cytoprotective gene expression. Here, we report-to our knowledge for the first time-biallelic inactivation of KEAP1 in NSCLC, which we believe would result in constitutive activation of NRF2.
###end p 77
###begin p 78
###xml 1128 1129 1128 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b005">5</xref>
In corroboration with the above findings that suggest loss of functional KEAP1 in lung cancers, immunohistochemical staining of NRF2 in lung adenocarcinoma tissues showed increased staining in tumor tissue compared to paired normal tissue. As anticipated, NQO1 and GST enzyme activities and GSH levels were significantly elevated in the tumors compared with those in the matched normal tissue. In the absence of functional KEAP1 activity, cancer cells demonstrated an increased nuclear accumulation of NRF2 as well as an increase in total NRF2. Predictably, the NQO1 and GSR enzyme activities and GSH levels were significantly higher in cancer cells. Expression analysis of NRF2-dependent genes revealed upregulation of antioxidant genes, detoxification enzymes, and drug efflux pumps in the cancer cells. GSH and related detoxification enzymes, including GSH-conjugating efflux pumps, are involved in the detoxification of anti-neoplastic drugs and by-products of oxidative stress. Upregulation of GSH and related enzymes in tumor tissues probably contributes to the observed high resistance to cytotoxic drugs and cell death [5].
###end p 78
###begin p 79
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b003">3</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b005">5</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b033">33</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b006">6</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b034">34</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b035">35</xref>
The high antioxidant capacity of NSCLC cells increases cell survival and proliferation and protects against oxidants, radiation, and chemotherapies, thus conferring the chemoresistance phenotype [3,5]. Levels of GSH-conjugating enzymes have been shown to be higher in cell lines derived from NSCLC cells than in small cell lung cancer cell lines [33]. Others have speculated that these alterations may account for the differences in drug sensitivity between these tumor types [6]. Several studies have documented that GSH concentrations are high in drug-resistant cancer cell lines and that cell viability can be modulated with buthionine sulfoximine, which causes GSH depletion [34,35].
###end p 79
###begin p 80
###xml 455 459 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b007">7</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b008">8</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b015">15</xref>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
Expression of the wild-type KEAP1 in H838 cells stably expressing an ARE reporter completely abolished ARE reporter activity, whereas overexpression of the KEAP1 mutant construct did not, suggesting that the somatic mutations hamper the association between KEAP1 and NRF2 and consequently activate NRF2. Critically, the enhanced expression of various antioxidants and detoxification genes was verified to be NRF2-dependent, because siRNA targeted against NRF2 transcript attenuated the expression of these NRF2-dependent genes in A549 cells. However, our understanding of NRF2-regulated genes is based on genomic profiling of Nrf2 wild-type and knock out mice in response to different environmental stress [7,8,15]. Other than the cellular antioxidants and xenobiotic enzymes, the global transcriptional program regulated by constitutive activation of NRF2 in tumor cells remains unknown. Elucidation of NRF2-dependent pathways in tumor cells will provide a better understanding of this novel chemoresistance factor.
###end p 80
###begin p 81
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b011">11</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b036">36</xref>
###xml 462 464 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b036">36</xref>
###xml 465 467 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030420-b037">37</xref>
###xml 525 531 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1,</italic>
###xml 618 623 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 733 738 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 810 815 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 1161 1166 1157 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 665 670 <span type="species:ncbi:9606">human</span>
###xml 703 708 <span type="species:ncbi:9606">human</span>
Increased NRF2 staining and NRF2-dependent enzyme activities in tumor samples with wild-type KEAP1 suggests that there are other possible mechanisms operating in tumor cells that contribute to increased stabilization and activation of NRF2 [11,36]. For example, Prothymosin alpha, an extremely abundant nuclear oncoprotein, has been recently demonstrated to be an intranuclear dissociator of NRF2-KEAP1 complex and to upregulate expression of NRF2 target genes [36,37]. Another possible mechanism is differential splicing of KEAP1, leading to nonfunctional KEAP1 protein product in cancer cells. Alternatively spliced KEAP1 transcript lacking exon 5 is reported in human large cell lung carcinoma (NCBI human genome database). Also, KEAP1 downregulation by promoter methylation cannot be ruled out because the KEAP1 promoter contains CpG-rich regions. It is also possible that chronic oxidative stress, resulting from increased metabolic activity in cancer cells, is contributing to activation of NRF2. Thus, more intensive studies are needed to unravel the mechanisms responsible for exaggerated NRF2 response in cancer cells even in the presence of wild-type KEAP1.
###end p 81
###begin p 82
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 816 822 816 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1,</italic>
###xml 1409 1417 <span type="species:ncbi:9606">patients</span>
In summary, though activation of the NRF2 pathway in normal cells confers cytoprotection against oxidative stress and carcinogens, unrestrained activation of the same transcriptional program in cancer cells may provide selective growth advantages to tumors over normal somatic cells. The identification of KEAP1 mutations in a subset of NSCLC samples and the association between loss of functional KEAP1 and increased NRF2 activity extends the emerging paradigm whereby increased expression of antioxidants, detoxification enzymes, and drug transporters favors malignant progression and renders tumors resistant to chemotherapy. While the number of tumors examined in this study is not sufficiently large to lead to a definitive conclusion, this study is the first to our knowledge to show that mutations and LOH in KEAP1, as well as possibly other non-mutation-based mechanisms, enable high NRF2 activity in primary lung tumors. It remains to be determined whether such a mechanism operates in cancers arising in other organs such as ovary, pancreas, brain, and breast, where chemoresistance is a major issue, and whether high NRF2 activity in tumors can be a biomarker of poor prognosis. If future experiments verify that enhanced activation of NRF2 is a key cause of chemoresistance and poor prognosis, one could envision development of specific siRNA or small molecule inhibitors of NRF2 for treatment of patients with tumors resistant to chemotherapy.
###end p 82
###begin title 83
Supporting Information
###end title 83
###begin title 84
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Sequence Analysis Reveals Mutations in KEAP1 in Lung Cancer Cell Lines and Tumor Tissues
###end title 84
###begin p 85
(A) Representative DNA sequence data from lung cancer cell lines. The wild-type sequences are from the non-malignant cell line BEAS2B. Only the mutant allele was detected in the cancer cell lines shown.
###end p 85
###begin p 86
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
(B) Representative electropherograms depicting some of the KEAP1 mutations identified in NSCLC tumors. All the mutations identified in patients were heterozygous.
###end p 86
###begin p 87
(122 KB PDF)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin title 89
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 26 31 <span type="species:ncbi:9606">Human</span>
LOH at the KEAP1 Locus in Human Primary Lung Tumors
###end title 89
###begin p 90
Representative electropherograms showing partial and complete loss of one allele and microsatellite instability at 19p13.2.
###end p 90
###begin p 91
(111 KB PPT)
###end p 91
###begin p 92
Click here for additional data file.
###end p 92
###begin title 93
Immunohistochemical Staining of NRF2 in NSCLC Tumor Tissue
###end title 93
###begin p 94
To demonstrate the specificity of anti-NRF2 antibody staining, we preincubated the anti-NRF2 antibody with luciferase (A) and NRF2 (B) in vitro transcribed and translated protein. Incubation of anti-NRF2 antibody with NRF2 protein significantly reduced the NRF2 staining.
###end p 94
###begin p 95
(5.8 MB PPT)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin title 97
Western Blot Showing Increased Nuclear NRF2 in Lung Cancer Cells(A) Second set of immunoblot showing increased nuclear localization of NRF2 in nuclear extracts (NE) from cancer cells.
###end title 97
###begin p 98
(B and C) Quantification of NRF2 and KEAP1 protein in immunoblots. For band densitometry, bands in nuclear extract blot (B) were normalized to Lamin B1 and those in total protein (C) were normalized to GAPDH.
###end p 98
###begin p 99
(581 KB PPT)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin title 101
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Pathological and KEAP1 Mutation Details of PTs and PF Samples
###end title 101
###begin p 102
(70 KB PDF)
###end p 102
###begin p 103
Click here for additional data file.
###end p 103
###begin title 104
Primer Sequences Used in Study
###end title 104
###begin p 105
(21 KB XLS)
###end p 105
###begin p 106
Click here for additional data file.
###end p 106
###begin title 107
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Details of Somatic Alterations in KEAP1 in Normal and Tumor-Derived Lung Cell Lines
###end title 107
###begin p 108
(22 KB XLS)
###end p 108
###begin p 109
Click here for additional data file.
###end p 109
###begin title 110
Total GSH and Enzyme Activities of NQO1 and GST in Matched NSCLC and Normal Tissues
###end title 110
###begin p 111
(22 KB XLS)
###end p 111
###begin p 112
Click here for additional data file.
###end p 112
###begin title 113
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
Real-Time Expression Analyses of KEAP1, NRF2, and NRF2-Dependent Genes by Real-Time RT-PCR
###end title 113
###begin p 114
(18 KB XLS)
###end p 114
###begin p 115
Click here for additional data file.
###end p 115
###begin title 116
Accession Numbers
###end title 116
###begin p 117
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCLC</italic>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCLM</italic>
###xml 173 176 173 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSR</italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP1</italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP2</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NQO1</italic>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRDX1</italic>
The National Center for Biotechnology Information () accession numbers for the genes and gene products discussed in this paper are GCLC (GeneID: 2729), GCLM (GeneID: 2730), GSR (GeneID: 2936), KEAP1 (GeneID: 9817), KEAP1 (NP_036421, NP_987096), MRP1 (GeneID: 4363), MRP2 (GeneID: 1244), NQO1 (GeneID: 1728), NRF2 (GeneID: 4780), NRF2 (NP_006155), and PRDX1 (GeneID: 5052).
###end p 117
###begin p 118
We thank Laura Kasch at the DNA fragment analysis facility at Johns Hopkins University for microsatellite-based genotyping services. We also thank the Statistics Core, Bloomberg School of Public Health, Johns Hopkins University, for assistance with statistical analyses.
###end p 118
###begin title 119
Abbreviations
###end title 119
###begin p 120
antioxidant response element
###end p 120
###begin p 121
broad complex, tramtrack, and bric-a-brac
###end p 121
###begin p 122
gamma-glutamyl cysteine synthetase catalytic subunit
###end p 122
###begin p 123
gamma-glutamyl cysteine synthetase modifier subunit
###end p 123
###begin p 124
glutathione
###end p 124
###begin p 125
glutathione reductase
###end p 125
###begin p 126
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
glutathione-S-transferase
###end p 126
###begin p 127
intervening region
###end p 127
###begin p 128
Kelch-like ECH-associated protein 1
###end p 128
###begin p 129
loss of heterozygosity
###end p 129
###begin p 130
multidrug resistance protein
###end p 130
###begin p 131
NADP(H) quinone oxidoreductase 1
###end p 131
###begin p 132
nuclear factor erythroid-2 related factor 2
###end p 132
###begin p 133
non-small-cell lung cancer
###end p 133
###begin p 134
pleural fluid
###end p 134
###begin p 135
peroxiredoxin
###end p 135
###begin p 136
primary tumor
###end p 136
###begin p 137
standard deviation
###end p 137
###begin title 138
References
###end title 138
###begin article-title 139
The treatment of advanced non-small cell lung cancer
###end article-title 139
###begin article-title 140
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations
###end article-title 140
###begin article-title 141
Glutathione-associated enzymes in anticancer drug resistance
###end article-title 141
###begin article-title 142
Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels
###end article-title 142
###begin article-title 143
Expression of gamma-glutamyl cysteine synthetase in nonsmall cell lung carcinoma
###end article-title 143
###begin article-title 144
Mechanisms of cancer drug resistance
###end article-title 144
###begin article-title 145
###xml 89 93 <span type="species:ncbi:10090">mice</span>
Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice
###end article-title 145
###begin article-title 146
Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray
###end article-title 146
###begin article-title 147
Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin
###end article-title 147
###begin article-title 148
###xml 132 137 <span type="species:ncbi:10090">mouse</span>
Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts
###end article-title 148
###begin article-title 149
Regulatory mechanisms controlling gene expression mediated by the antioxidant response element
###end article-title 149
###begin article-title 150
Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene
###end article-title 150
###begin article-title 151
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust
###end article-title 151
###begin article-title 152
Nrf2 is a critical regulator of the innate mmune response and survival during experimental sepsis
###end article-title 152
###begin article-title 153
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice
###end article-title 153
###begin article-title 154
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice
###end article-title 154
###begin article-title 155
Cancer chemoprevention: Scientific promise, clinical uncertainty
###end article-title 155
###begin article-title 156
Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels
###end article-title 156
###begin article-title 157
Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2
###end article-title 157
###begin article-title 158
Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex
###end article-title 158
###begin article-title 159
The kelch repeat superfamily of proteins: Propellers of cell function
###end article-title 159
###begin article-title 160
Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers
###end article-title 160
###begin article-title 161
Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation
###end article-title 161
###begin article-title 162
Structural basis for defects of keap1 activity provoked by its point mutations in lung cancer
###end article-title 162
###begin article-title 163
Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues
###end article-title 163
###begin article-title 164
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering
###end article-title 164
###begin article-title 165
###xml 78 83 <span type="species:ncbi:9606">human</span>
Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types
###end article-title 165
###begin article-title 166
High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity
###end article-title 166
###begin article-title 167
###xml 82 87 <span type="species:ncbi:9606">human</span>
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2
###end article-title 167
###begin article-title 168
Genetic and epigenetic alterations of BRG1 promote oral cancer development
###end article-title 168
###begin article-title 169
Molecular genetics of lung cancer
###end article-title 169
###begin article-title 170
Hereditary cancer, oncogenes, and antioncogenes
###end article-title 170
###begin article-title 171
Topoisomerase-targeting antitumor drugs
###end article-title 171
###begin article-title 172
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance
###end article-title 172
###begin article-title 173
Glutathione analogues in cancer treatment
###end article-title 173
###begin article-title 174
Nuclear oncoprotein prothymosin alpha is a partner of Keap1: Implications for expression of oxidative stress-protecting genes
###end article-title 174
###begin article-title 175
Expression of the prothymosin-a gene as a prognostic factor in lung cancer
###end article-title 175
###begin title 176
Figures and Tables
###end title 176
###begin title 177
###xml 47 52 <span type="species:ncbi:9606">Human</span>
Schematic of the Conserved Domain Structure of Human KEAP1 Protein
###end title 177
###begin p 178
###xml 440 447 440 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030420-t001">Table 1</xref>
The protein consists of an N-terminal region (amino acids 1-60), a BTB domain (amino acids 61-179), a central IVR (amino acids 180-314), a double-glycine-rich region comprising six Kelch motifs (amino acids 315-359, 361-410, 412-457, 459-504, 506-551, and 553-598), and a C-terminal domain (amino acids 599-624). The frequency of mutations detected within each domain is indicated below. Amino acid positions of the mutations are listed in Table 1.
###end p 178
###begin title 179
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
Somatic Alterations in KEAP1 in Lung Cancer
###end title 179
###begin p 180
(A) LOH at the 19p13.1-13.3 region. A heat map depicts microsatellite-based LOH at 19p13.1-19p13.3 in 181 lung cancer cell lines. Tumor-derived cell lines that were non-informative for this region were not included. Microsatellite markers showing heterozygous typings are depicted in red, markers demonstrating homozygous typing are in green, and non-informative markers in black. Each vertical column represents one cell line. ET, endocrine tumors; NS, no subtype specified; SCC, small cell carcinoma.
###end p 180
###begin p 181
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
(B) Sequence analysis of KEAP1 mutations in lung cancer. Part a shows the H838 cell line showing C-A substitution (G-T, plus strand), resulting in a termination codon. Wild-type sequence is from BEAS2B. A wild-type allele was not detected in H838. Part b shows a 18-bp deletion in one allele but not in the other allele in the PF DNA sample from PF-8. Part c shows tumor PT-23, showing A-T substitution in one allele but not in the other allele. Part d shows a 2-bp deletion in the fourth exon of KEAP1 that was detected in one allele of PT-17. Samples showing deletion mutations were confirmed by subcloning and sequencing.
###end p 181
###begin p 182
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 277 285 277 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-UM1</italic>
###xml 289 291 289 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sub>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 337 345 337 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP-DM1</italic>
###xml 349 351 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21</sub>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
(C) LOH at the KEAP1 locus in human primary lung tumors. Summary of LOH patterns of 39 NSCLC tumors. Retained microsatellites are indicated in red, markers demonstrating allelic loss in green, markers showing genomic instability in white, and non-informative markers in black. KEAP-UM1 (CA17) is present upstream of the KEAP1 locus, and KEAP-DM1 (CA21) is present downstream of the KEAP1 locus.
###end p 182
###begin title 183
Dysfunctional KEAP1-NRF2 Interaction in NSCLC Tumors
###end title 183
###begin p 184
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 74 81 <span type="species:ncbi:9606">patient</span>
###xml 177 184 <span type="species:ncbi:9606">patient</span>
###xml 265 272 <span type="species:ncbi:9606">patient</span>
###xml 430 437 <span type="species:ncbi:9606">patient</span>
(A) Immunohistochemical analysis of NRF2 in NSCLC tissues. Part a shows a patient (PT-18) with mutation in KEAP1 showing strong nuclear and cytoplasmic staining. Part b shows a patient negative for mutation (PT-28) showing weak cytoplasmic staining. Part c shows a patient negative for mutation (PT-20) showing increased nuclear and cytoplasmic staining in tumor tissue. Part d shows weakly staining normal bronchus from the same patient (PT-20).
###end p 184
###begin p 185
###xml 139 147 139 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st004">Table S4</xref>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
(B) Total GSH and enzyme activities of NQO1 and total GST in NSCLC and matched normal tissues. Raw data for the heat maps are presented in Table S4. *, samples harboring KEAP1 mutation; section sign, nmol/mg protein; dagger, nmol DCPIP reduced/min/mg protein; double dagger, nmol of product formed/min/mg protein.
###end p 185
###begin title 186
Status of KEAP1 and NRF2 Is Altered in Cancer Cells
###end title 186
###begin p 187
(A) Immunoblot showing increased nuclear localization of NRF2 in nuclear extracts (NE) from cancer cells. Cancer cells showed lower levels of KEAP1 (~69 kDa) and higher levels of NRF2 (~110 kDa) in total protein lysates (TP). NIVT and KIVT indicate NRF2 and KEAP1 in vitro transcribed/translated product, respectively.
###end p 187
###begin p 188
(B and C) Quantification of NRF2 and KEAP1 protein in immunoblots. For band densitometry, bands in nuclear extract blot (B) were normalized to Lamin B1, and those in total protein (C) were normalized to GAPDH.
###end p 188
###begin p 189
###xml 44 56 44 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1, NRF2,</italic>
###xml 147 155 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030420-st005">Table S5</xref>
(D) Heat map showing relative expression of KEAP1, NRF2, and NRF2-dependent genes by real-time RT-PCR. Raw data for the heat maps are presented in Table S5.
###end p 189
###begin title 190
Comparison of Total GSH Levels, GST, NQO1, and GSR Enzyme Activities between Cancer Cells and Normal Cells
###end title 190
###begin p 191
###xml 117 120 115 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 128 131 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 144 147 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 160 163 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 199 200 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Shown are total GSH levels (A) and enzyme activities for GST (B), NQO1 (C), and GSR (D). Data represent mean +/- SD (n = 3). *, p = 0.0016; **, p = 0.039; ***, p = 0.011 relative to normal cells (by t-test).
###end p 191
###begin title 192
Mutant KEAP1 Protein Is Unable to Suppress NRF2 Activity
###end title 192
###begin p 193
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
###xml 238 241 236 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
(A) Repression activity of the KEAP1 mutants was monitored by a luciferase reporter assay. Wild-type and mutant KEAP1 cDNA constructs were transfected onto H838 cells stably expressing ARE luciferase reporter. Data represent mean +/- SD (n = 3).
###end p 193
###begin p 194
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRF2</italic>
(B) Silencing of NRF2 by siRNA in A549 cells downregulated the expression of NRF2-dependent genes. A nonspecific siRNA (NS siRNA) was used as control.
###end p 194
###begin p 195
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KEAP1</italic>
(C) Inhibition of KEAP1 expression by siRNA in BEAS2B cells upregulated the expression of NRF2-dependent genes.
###end p 195
###begin title 196
Increased NRF2 Activity Confers Chemoresistance
###end title 196
###begin p 197
BEAS2B cells and cancer cells were exposed to etoposide (A) or carboplatin (B) for 72 h, and viable cells were determined by MTT assay. BEAS2B cells displayed enhanced sensitivity whereas cancer cells with dysfunctional KEAP1 activity demonstrated reduced chemosensitivity to etoposide and carboplatin treatment. Data are presented as percentage of viable cells relative to the vehicle-treated control. Data are the mean of eight independent replicates, combined to generate the mean +/- SD for each concentration.
###end p 197
###begin p 198
###xml 64 72 <span type="species:ncbi:9606">Patients</span>
KEAP1 Sequence Alterations in Lung-Tumor-Derived Cell Lines and Patients
###end p 198
###begin p 199
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 199
###begin p 200
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 228 233 <span type="species:ncbi:9606">human</span>
Author contributions. AS, SBB, and SB designed the experiments. AS, VM, RKT, HL, SA, and EG performed the experiments. AS, MOH, DS, and SB were involved in data analysis. MB was involved in collection and maintenance of all the human tissue samples. JGH provided all the cancer cell lines. SB contributed reagents/materials. AS, JGH, SBB, DS, and SB contributed to writing the paper.
###end p 200
###begin p 201
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported by National Institutes of Health grants P50 CA058184 (SBB), HL081205 (SB), and P30 ES 038819 and by a Young Clinical Scientist Award from the Flight Attendant Medical Research Institute (SB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 201

